CHRS Jan 2026 2.000 call
| Previous Close | 0.9500 |
| Open | 0.9500 |
| Bid | 0.5000 |
| Ask | 5.0000 |
| Strike | 2.00 |
| Expire Date | 2026-01-16 |
| Day's Range | 0.9500 - 0.9500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 188 |
GlobeNewswireCoherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
Former Global Controller of Merck & Co., Inc. Enhances Financial, Operational and Strategic Transformational Expertise Rita Karachun Rita Karachun - Coherus Director REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice President (SVP) and Global Controller for Merck & Co., Inc., (Merck) was appointed to its Board of Directors effective May 31, 2024. Ms. Kar
GlobeNewswireCoherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T cells (Tregs) was observed and depletion was maintained over the dosing interval, establishing proof of mechanism Preclinical data and preliminary clinical results support further evaluation of CHS-114 in combination with the anti-programmed cell death protein 1 (PD-1) antibody, toripalimab-tpzi, and other
Simply Wall St.We Think Some Shareholders May Hesitate To Increase Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation
Key Insights Coherus BioSciences to hold its Annual General Meeting on 29th of May Salary of US$982.9k is part of CEO...
